Abbott, Australian Blood Service ink agreement for Alinity System

Published On 2019-10-26 03:45 GMT   |   Update On 2021-08-16 06:06 GMT

New Delhi: Abbott recently announced the Australian Red Cross Blood Service (Australian Blood Service) has signed a multiple-year agreement for Abbott's most first blood and plasma screening technology, Alinity System. The Australian Blood Service collects 1.5 million donations each year, providing a safe blood supply to 25 million Australians.


The agreement also includes Abbott's total lab automation solution, as well as its informatics and professional services. The Australian Blood Service staff will use AlinIQ AMS (Analyzer Management System), a product of AlinIQ Professional Services, to integrate data from multiple analyzers so staff can view it in one place, providing greater workflow efficiency and better quality control. The Alinity s system will help continuously process up to 600 tests per hour, while the lab automation solution will manage routine, manual tasks so staff can handle up to 3,600 samples per hour.


Read Also: Abbott, Tandem Diabetes Care explore integrated solutions to improve diabetes management


The adoption of Abbott's latest technologies allows the Australian Blood Service to bring the highest levels of efficiency to their operation. By updating Abbott's previous blood and plasma screening system with Alinity s, and adding total lab automation to their facilities, the Australian Blood Service will be able to further improve workflow practices and productivity.


"For the past 30 years, we've partnered with the Australian Blood Service to help ensure people in Australia have access to a safe blood supply," said Louis Morrone, vice president, Transfusion Medicine, Abbott. "By combining Abbott's latest advancements in blood and plasma screening with the benefits of automation and informatics technology customized to their organization, the Australian Blood Service can ensure the highest levels of quality to safeguard their blood supply for years to come."


Read Also: Abbott neurostimulation system Proclaim XR gets USFDA nod for chronic pain

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News